Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
The development of imatinib for the treatment of chronic myeloid leukemia (CML) has proven to be an example of medical success in the era of targeted therapy. However, imatinib resistance or intolerance occurs in a substantial number of patients. Additionally, patients who have progressed beyond the...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2009
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726068/ |